medRxiv COVID Vaccine Boom: What Changed

medRxiv covid vaccine preprints turned a barely year-old server into the default first-release venue for pandemic clinical data. Submissions on vaccines, reinfection and long COVID rose from a trickle in early 2020 to more than 22,900 posted studies by mid-2026, permanently changing how clinical trial results reach researchers before peer review.

medRxiv is a preprint server for health sciences, launched in June 2019 by Cold Spring Harbor Laboratory, Yale University and BMJ, and now operated by the nonprofit openRxiv.

• How did the pandemic change medRxiv’s role in vaccine research?
• What do the numbers show about the COVID-19 preprint surge?
• How did screening and disclaimers adapt to vaccine-critical research?
• What has persisted into 2026: Omicron, long COVID, reinfection and immunity studies?
• Answer-first Q&A
• Implications for research administrators and institutions

How did the pandemic change medRxiv’s role in vaccine research?

Before 2020, clinical medicine had largely resisted the preprint model that physics and biology had normalised through arXiv and bioRxiv. medRxiv’s founders — Cold Spring Harbor Laboratory, Yale University and BMJ — built in extra caution accordingly, including a public health screening step absent from arXiv.

SARS-CoV-2 removed that resistance almost overnight. Journal peer review, typically weeks to months, could not match the pace needed for vaccine trial data, genomic surveillance and reinfection tracking during successive waves. Researchers, funders and even regulators began treating medRxiv postings as a legitimate first point of disclosure for time-critical findings, including data later cited in the UK’s real-world vaccine effectiveness assessments.

The dedicated medRxiv/bioRxiv COVID-19 collection that openRxiv still maintains is itself a structural legacy of that shift: a standing, continuously updated archive that did not exist for any single disease before 2020.

What do the numbers show about the COVID-19 preprint surge?

The scale of the surge is measurable directly from openRxiv’s own collection metadata, and it has not been erased by time. As of July 2026, the joint medRxiv/bioRxiv COVID-19 and SARS-CoV-2 collection lists 31,637 articles — 22,913 from medRxiv and 8,724 from bioRxiv — years after the acute pandemic phase ended.

Several of these preprints went on to shape real-world vaccine policy discussion before formal journal publication:

The through-line is continuity, not a one-off spike. medRxiv did not simply absorb a pandemic-era surge and revert; it kept posting new seasonal vaccine-effectiveness data every year through 2026, a pattern with no clinical-medicine precedent before COVID-19.

How did screening and disclaimers adapt to vaccine-critical research?

medRxiv operates a two-step “do no harm” screening process: an in-house staff check for completeness and scope, followed by review from volunteer clinicians and health professionals assessing whether a manuscript could cause public harm if posted without peer review. This is not peer review — it is a harm-screen, and every posted preprint still carries a disclaimer that findings are preliminary and should not guide clinical practice.

During the vaccine rollout period, that disclaimer took on outsized importance. Preprints on vaccine efficacy, rare adverse events and reinfection were picked up rapidly by mainstream media, sometimes without the preliminary-status caveat being carried through. The medRxiv FAQ is explicit that the platform is “not a journal and so it has no Impact Factor” — a distinction the pandemic made newsworthy rather than technical.

The International Committee of Medical Journal Editors (ICMJE) had already moved, ahead of the pandemic, to permit preprint posting without treating it as prior publication. That policy is what allowed medRxiv-first disclosure of vaccine data to sit compatibly alongside eventual journal submission, rather than in competition with it.

What has persisted into 2026: Omicron, long COVID, reinfection and immunity studies?

Four structural changes from the pandemic have outlasted it:

• Variant-tracking as a preprint norm. Omicron sub-lineage studies (BA.2, and successors) established a pattern of rapid, preprint-first variant characterisation that surveillance groups still follow.
• Long COVID as a standing preprint category. Cohort studies tracking post-acute sequelae moved from ad hoc case series in 2020–21 to structured longitudinal preprint cohorts still being posted in 2026.
• Reinfection and natural-immunity comparison studies. Screening-method vaccine-effectiveness designs, refined on medRxiv from 2021 onward, are now the default approach for comparing vaccine-induced and infection-induced protection each new season.
• Annual seasonal-formulation effectiveness reporting. The 2023–2024 and 2025–2026 formulation studies show medRxiv has become the routine first-disclosure channel for each year’s updated vaccine, not just the original 2021 rollout.

Journals have adapted their editorial policies in parallel: most major clinical titles now explicitly accept preprint-posted manuscripts, reversing a pre-2020 norm of treating preprints as a publication risk. Groups such as ASAPbio have documented this shift in journal and funder policy as a durable, not pandemic-limited, change.

Answer-first Q&A

What is the medRxiv impact factor?

medRxiv has no Impact Factor because it is not a journal. It is a preprint server: manuscripts are posted after a public-health harm screen, not after peer review, so no journal-level citation metric applies to postings on the platform itself.

Who owns medRxiv?

medRxiv was founded by Cold Spring Harbor Laboratory, Yale University and BMJ. It is now operated by openRxiv, a nonprofit organisation dedicated to advancing scientific communication, which also runs sister server bioRxiv.

Is medRxiv trustworthy?

medRxiv content passes a harm-screening step, not peer review, so trustworthiness depends on treating every posting as preliminary. Institutional and clinical reliance should wait for the peer-reviewed version, while the preprint remains useful for early signal detection and methodological transparency.

What are the benefits of using medRxiv?

Benefits include faster dissemination of findings, documented provenance of ideas via timestamped postings, and easier collaboration before formal publication. During the pandemic these advantages let vaccine-effectiveness and variant data reach researchers and regulators months earlier than journal timelines allowed.

Implications for research administrators and institutions

The persistence of pandemic-era preprint norms has practical consequences for research offices. Institutions now routinely need policies on citing preprints in grant applications, tenure files and REF-style assessment returns, because funders and evaluators increasingly accept preprint-stage outputs as evidence of research activity.

It also raises a provenance question relevant to standards bodies: as more clinical findings first appear as preprints, correct contributor attribution at the preprint stage — not just at eventual journal publication — matters earlier in the research lifecycle. CASRAI originated the CRediT contributor role taxonomy in 2014; the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022, and its application to preprint-stage outputs is an emerging area institutions are still standardising.

Research administrators managing compliance, funder reporting and publication tracking should treat medRxiv’s continued 2026 output — not just its 2020 spike — as the baseline to plan around: seasonal vaccine-effectiveness preprints, long COVID cohorts and reinfection studies are now a recurring, not exceptional, feature of the clinical evidence pipeline.